Sequential Single-Cell Transcriptional and Protein Marker Profiling Reveals TIGIT as a Marker of CD19 CAR-T Cell Dysfunction in Patients with Non-Hodgkin Lymphoma.
Zachary JacksonChangjin HongRobert SchaunerBoro DropulićPaolo F CaimiMarcos J deLimaMaria Florencia GiraudoKalpana GuptaJane S ReeseTae Hyun HwangDavid N WaldPublished in: Cancer discovery (2022)
This is the first study investigating the mechanisms linked to CAR-T patient responses based on the sequential analysis of manufactured and infused CAR-T cells using single-cell RNA and protein expression data. Furthermore, our findings are the first to demonstrate an improvement of CAR-T cell efficacy with TIGIT inhibition alone. This article is highlighted in the In This Issue feature, p. 1825.